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Introduction
This Comment provides a summary of the Supreme Court’s most
recent decision analyzing the bounds of patent eligibility: Mayo
Collaborative Services v. Prometheus Laboratories, Inc. 1 In this
March 2012 decision, the Court significantly departed from the Federal
Circuit’s 2 prevalent use of the “machine-or-transformation test” for
determining the limits of patentable subject matter. 3 The Court
unanimously reversed the Federal Circuit’s decision in favor of
1.

Mayo Collaborative Servs. v. Prometheus Labs., Inc., 132 S. Ct. 1289
(2012).

2.

The United States Court of Appeals for the Federal Circuit was established
in 1982 and has nationwide jurisdiction over patent law appeals arising from
any United States District Court. Court Jurisdiction, U.S. Ct. Appeals
for Fed. Circuit, http://www.cafc.uscourts.gov/the-court/court-juris
diction.html (last visited Oct. 27, 2012).

3.

See Mayo, 132 S. Ct. at 1303 (precluding the “machine-or-transformation”
test from trumping the “law of nature” exclusion).
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Prometheus and found that the correlation between thiopurine drug
dosage and a patient’s subsequent metabolic response amounted to an
unpatentable law of nature. 4
The synopsis herein is intended as a general overview of subject
matter that is patentable under 35 U.S.C. § 101, as well as the impact
of the Mayo decision on patent examination and patent eligibility. 5
Thus, this Comment is predominantly intended for nonspecialists, as
it does not scrutinize the scientific principles of Prometheus’s patents
or the decision’s overall impact on the field of medical technology. 6
Part I of this Comment provides a brief introduction to the statutory
bounds of patentable subject matter under 35 U.S.C. § 101. Part II
summarizes the patents at issue in Mayo and the complex history of
Prometheus’s dispute. That section goes on to clarify the meaning and
impact of the Court’s landmark interpretation regarding the patent
eligibility of natural laws. Finally, Part III discusses the effect of the
Mayo ruling on patent examination procedures at the United States
Patent and Trademark Office and the holding’s potential impact on
pending Federal Circuit cases.

I.

Patent Eligibility: The Merger of Statutory
Guidance Under 35 U.S.C. § 101 and
Patent Law Precedent

Under 35 U.S.C. § 101, a patent is conferred upon “[w]hoever invents
or discovers any new and useful process, machine, manufacture, or
composition of matter, or any new and useful improvement thereof,”
subject to the additional requirements of the Patent Act. 7 In a broad
sense, § 101 acts as a threshold to patentability by distinguishing
between the discovery of an existing principle versus the creation of an
original invention. Of course, the subsequent questions of whether an
4.

Id. at 1292, 1305.

5.

Given the sweeping reform to United States patent law that will stem
from the March 2013 implementation of the Leahy-Smith America
Invents Act, it is important to note that the text of 35 U.S.C. § 101 will
remain unchanged. The only mention of § 101 in Leahy-Smith notes
that “[n]othing in this section shall be construed as amending or
interpreting categories of patent-eligible subject matter set forth under
section 101 of title 35, United States Code.” Leahy-Smith America
Invents Act, Pub. L. No. 112-29, § 18(e), 125 Stat. 284, 331 (2011).

6.

Following oral arguments in the Mayo decision, SCOTUSblog reported
that “[t]he Supreme Court finished an hour of oral argument . . . on a
highly complex patent case, seemingly as deep in confusion at the end as
at the beginning . . . .” Lyle Denniston, Argument Recap: For Want of
a Good Hypothetical, SCOTUSblog (Dec. 7, 2011, 4:43 PM),
http://www.scotusblog.com/2011/12/argument-recap-for-want-of-a-good
-hypothetical.

7.

35 U.S.C. § 101 (2006).
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invention is novel, 8 nonobvious, 9 and adequately filed 10 are critical
inquiries that encompass the bulk of patent examination and
litigation. 11 But in order to warrant further examination, an inventor
must first overcome the subject matter eligibility threshold of § 101. 12
The underlying premise of patent law is to incentivize progress
and innovation by rewarding an inventor with the right to exclude
others from capitalizing upon his advancements for a particular period
of time. 13 To grant an inventor a monopoly over a general scientific
rule would directly counteract patent law’s purpose of promoting
innovation. 14 Thus, even celebrated breakthroughs such as Newton’s
law of gravity and Einstein’s revelation that E=mc2 would not
constitute patentable subject matter. 15 Although such discoveries were
previously unknown and groundbreaking scientific advancements, the
concepts as a whole describe existing natural laws and do not satisfy
the patentability requirements of § 101. 16
Thus, the policy rationale behind subject matter inquiries—and
patent law as a whole—is to balance an individual’s right to capitalize
upon his invention against the risk of hindering innovation by
imposing an effective monopoly through patenting. 17 The Mayo Court
8.

35 U.S.C. § 102.

9.

35 U.S.C. § 103.

10.

35 U.S.C. § 112.

11.

Although § 101 contains the somewhat misleading “new and useful”
language, the question of whether an invention satisfies the threshold of
patentable subject matter discussed herein is wholly separate from the
subsequent considerations of statutory novelty and nonobviousness. See
Diamond v. Diehr, 450 U.S. 175, 190–91 (1981) (noting that an
invention may fail either the nonobvious or novelty requirements but
still satisfy the threshold requirement for patent protection under
§ 101).

12.

Id.

13.

Diamond v. Chakrabarty, 447 U.S. 303, 307 (1980). Patent law in the
United States originates from Congress’s constitutional power to
“promote the Progress of Science and useful Arts, by securing for
limited Times to Authors and Inventors the exclusive Right to their
respective Writings and Discoveries.” U.S. Const. art. I, § 8, cl. 8.

14.

See Mayo Collaborative Servs. v. Prometheus Labs. Inc., 132 S. Ct.
1289, 1293 (2012) (“[M]onopolization of [scientific] tools through the
grant of a patent might tend to impede innovation more than it would
tend to promote it.”).

15.

Id.

16.

See Diehr, 450 U.S. at 185 (“A principle, in the abstract, is a
fundamental truth; an original cause; a motive; these cannot be
patented, as no one can claim in either of them an exclusive right.”
(quoting Le Roy v. Tatham, 55 U.S. (14 How.) 156, 175 (1853))).

17.

Mayo, 132 S. Ct. at 1293.
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described the balance between rewarding innovation and protecting
the public domain:
Patent protection is, after all, a two-edged sword. On the one
hand, the promise of exclusive rights provides monetary
incentives that lead to creation, invention, and discovery. On
the other hand, that very exclusivity can impede the flow of
information that might permit, indeed spur, invention, by, for
example, raising the price of using the patented ideas once
created, requiring potential users to conduct costly and timeconsuming searches of existing patents and pending patent
applications, and requiring the negotiation of complex licensing
arrangements. 18

Both courts and commentators frequently cite the notion that an
inventor may patent “anything under the sun that is made by man.” 19
In practice, though, such a broad statement is ambiguous and
somewhat misleading. Defining the precise bounds of what constitutes
a patentable “process, machine, manufacture, or composition of
matter” under § 101 has been a source of considerable debate, given
the vague language of the statute and the fast pace of scientific
advancements. Although not explicit in the language of § 101, courts
are bound by the fundamental precedent that “laws of nature,
physical phenomena, and abstract ideas” are not patentable subject
matter. 20 The purpose of these exceptions is to bar an inventor from
monopolizing discoveries that are “manifestations of . . . nature, [that
must remain] free to all men and reserved exclusively to none.” 21
Although laws of nature, physical phenomena, and abstract ideas
are never patentable, the boundaries that these exceptions encompass
are frequently less straightforward than the aforementioned examples
of attempting to patent gravity or the law of relativity. In Diamond
v. Diehr, the Supreme Court noted that “‘a process is not
unpatentable simply because it contains a law of nature or a
mathematical algorithm,’” because, in fact, “an application of a law of
18.

Id. at 1305.

19.

See Diamond v. Chakrabarty, 447 U.S. 303, 309 (1980) (noting that the
Committee Reports of the 1952 Patent Act provide the origin of the
famous “anything under the sun” language); Helen M. Berman &
Rochelle C. Dreyfuss, Reflections on the Science and Law of Structural
Biology, Genomics, and Drug Development, 53 UCLA L. Rev. 871, 873
(2006) (discussing the Supreme Court’s broad “anything under the sun”
language and its implications for patent law).

20.

Chakrabarty, 447 U.S. at 309, 315 (“Congress has performed its
constitutional role in defining patentable subject matter in § 101; we
perform ours in construing the language Congress has employed.”).

21.

Id. at 309 (first alteration in original) (quoting Funk Bros. Seed Co. v.
Kalo Inoculant Co., 333 U.S. 127, 130 (1948)).
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nature or mathematical formula to a known structure or process may
well be deserving of patent protection.” 22 In Diehr, the Court
analyzed whether a mathematical formula, the Arrhenius equation,
was a patentable matter within a process for curing synthetic
rubber. 23 The Court held that although the “Arrhenius equation is not
patentable in isolation,” the inventors merely incorporated the
equation to calculate optimal cure time, and the patent as a whole
provided an innovative, new approach to the entire precision molding
process. 24 Thus, the Court held that the “process [was] at the very
least not barred at the threshold by § 101.” 25
The boundary that separates prohibited recitations of natural
laws from permissible applications of the same natural laws is unclear
and thus a prime target for litigation. Mayo was the most recent
effort by the Court to clarify where, precisely, this boundary exists. 26

II. Opposite Sides of a Bright-Line Rule:
The Conflicting Conclusions of the Federal Circuit
and the Supreme Court
Prometheus was the exclusive licensee of U.S. Patent No.
6,355,623 27 and U.S. Patent No. 6,680,302. 28 In essence, the process
protected by the patents instructed medical personnel to first
administer a thiopurine drug to a patient and thereafter to measure
the metabolites in a sample of the patient’s blood. 29 The medical
22.

Diamond v. Diehr, 450 U.S. 175, 187 (1981) (first emphasis added)
(quoting Parker v. Flook, 437 U.S. 584, 590 (1978)). Diehr was decided
in the year following Chakrabarty, and together the two cases redefined
the methods of analyzing subject matter patentability. See id. at 181–82
(discussing the history of subject matter patentability and citing
Chakrabarty)).

23.

Id. at 177.

24.

Id. at 188.

25.

Id.

26.

See Mayo Collaborative Servs. v. Prometheus Labs. Inc., 132 S. Ct.
1289, 1297 (2012) (“To put the matter more precisely, do the patent
claims add enough to their statements of the correlations to allow the
processes they describe to qualify as patent-eligible processes that apply
natural laws?”).

27.

Method of Treating IBD/Crohn’s Disease & Related Conditions
Wherein Drug Metabolite Levels in Host Blood Cells Determine
Subsequent Dosage, U.S. Patent No. 6,355,623 (filed Apr. 8, 1999).

28.

Methods of Optimizing Drug Therapeutic Efficacy for Treatment of
Immune-Mediated Gastrointestinal Disorders, U.S. Patent No. 6,680,302
(filed Dec. 27, 2001).

29.

Adam Liptak, Justices Back Mayo Clinic Argument on Patents, N.Y.
Times, Mar. 21, 2012, at B3.
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researchers behind the invention calculated the optimal ratios of the
drug dosage to the patient’s blood sample in order to maximize the
dosage’s efficiency while minimizing the risk of overdose. 30 Thus, the
final aspect of the patented process indicated that a doctor should
adjust the amount of thiopurine subsequently administered to the
patient based on these precise ratios. 31
Thiopurine drugs are typically administered to treat
gastrointestinal disorders such as ulcerative colitis and Crohn’s
disease. 32 Prior to the patents’ claimed discoveries, researchers in the
field understood the general relationship between the dosage of
thiopurine relative to the amount of metabolites in a patient’s blood;
however, medical researchers had not established any sort of precise
test to evaluate the correlation or determine the likely effectiveness of
the medicine. 33
Prometheus developed the patented research into tangible
diagnostic tests for medicinal use. 34 As the exclusive licensee of the
technology, Prometheus sold the diagnostic tests to Mayo Medical
Laboratories and Mayo Collaborative Services. 35 In June 2004, Mayo
announced the company’s intention to begin marketing its own
diagnostic test with similar—though not precisely the same—
thiopurine dosage parameters, and thus Mayo effectively terminated
its relationship with Prometheus. 36 Immediately following Mayo’s
announcement, Prometheus Laboratories sued for patent infringement
on June 15, 2004. 37
A. Mayo’s Inescapable Ties to the
Parallel Bilski v. Kappos Proceedings

Prometheus’s lengthy, and ultimately unsuccessful, effort to
uphold their patents’ validity was riddled with unusual procedural
twists. Initially, the United States District Court for the Southern
30.

Id.

31.

More precisely, the patents claimed the diagnostic correlation between
the dosage of thiopurine and the concentration of 6-TG or 6-MMP
metabolite in a patient’s blood. Mayo, 132 S. Ct. at 1295.

32.

Id. at 1294–95.

33.

Id. at 1295.

34.

Id. The Prometheus Laboratories website features various diagnostic
tests sold by the company. See Products and Services: Diagnostics,
Prometheus, http://www.prometheuspatients.com/Products_Diagnost
ics.asp (last visited Dec. 19, 2012).

35.

Mayo, 132 S. Ct. at 1295.

36.

Prometheus Labs., Inc. v. Mayo Collaborative Servs., No. 04cv1200 JAH
(RBB), 2008 WL 878910, at *1 (S.D. Cal. Mar. 28, 2008).

37.

Id.
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District of California found the Prometheus patents to be invalid and
granted summary judgment in favor of Mayo. 38 The court concluded
that the patents simply claimed correlations between thiopurine levels
and the drug’s therapeutic effects, and thus the patents were no more
than a recitation of data-gathering steps for evaluating natural
phenomena. 39
It is crucial to emphasize that the District Court’s decision came
in March 2008. 40 Given the infrequency of § 101 patent eligibility
questions reaching the Supreme Court, it is important to note that
the short time span of 2008 through 2012 included two important
§ 101 patent litigations running in parallel to one another. 41 The first,
Mayo, questioned the patentability of laws of nature; the second,
Bilski v. Kappos, questioned the patentability of an abstract idea. 42
At nearly the precise midpoint of the one year span between Mayo’s
District Court decision and subsequent Federal Circuit appeal, the
Federal Circuit in Bilski declared the so-called “machine-ortransformation test” as the definitive mechanism for determining a
patent’s § 101 eligibility. 43 The machine-or-transformation test is a
test of whether an invention for a process or method “is (1) tied to a
particular machine or apparatus, or (2) transforms a particular article
to a different state or thing.” 44
Thus, on the aforementioned appeal by Prometheus in September
2009, the Federal Circuit reversed the District Court’s ruling based on
their use of Bilski’s machine-or-transformation test as a bright-line
rule. 45 The Federal Circuit held that the steps of administering a
certain amount of the thiopurine drug in relationship to the patient’s
metabolite levels were “transformative methods of treatment, not
38.

Id.

39.

Id. at *6

40.

Id. at *1.

41.

There is the possibility of a third § 101 opinion reaching the Court in an
upcoming term. For further discussion, see infra Part III.B.

42.

See In re Bilski, 545 F.3d 943, 949 (Fed. Cir. 2008) (noting that the
patent at issue covered a business method process for evaluating risk in
price changes, which necessitated the subject matter analysis of abstract
ideas), aff’d sub nom. Bilski v. Kappos, 130 S. Ct. 3218 (2010).

43.

Id. at 956 (reaffirming in October 2008 “that the machine-ortransformation test properly applied, is the governing test for
determining patent eligibility of a process under § 101.”).

44.

Memorandum from John J. Love, Deputy Comm’r for Patent
Examination Policy, on Guidance for Examining Process Claims in view
of In re Bilski (Jan. 7, 2009), available at http://www.uspto.gov/
patents/resources/methods/bilski_guidance_memo.pdf.

45.

Prometheus Labs., Inc. v. Mayo Collaborative Servs., 581 F.3d 1336,
1349–50 (Fed. Cir. 2009).
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correlations,” because “[t]he inventive nature of the claimed methods
stems . . . from the application of a natural phenomenon in a series of
transformative steps comprising particular methods of treatment.” 46
Bilski reached the Supreme Court first, and the Court reassessed
the importance of the machine-or-transformation test, declaring that
it was simply “a useful and important clue” in evaluating patent
eligibility, rather than the bright-line definitive rule for subject matter
patentability. 47 The next day, the Court granted certiorari in Mayo
and summarily reversed and remanded in light of Bilski. 48
When Mayo subsequently reached the Federal Circuit for a second
time in 2010, the case was closely watched for its potentially
widespread impact on the “personalized medicine” field. 49 However,
rather anticlimactically, the Federal Circuit once again relied on the
machine-or-transformation test and reaffirmed its decision in favor of
Prometheus. 50 The Federal Circuit elaborated upon the transformative
aspect of the patented invention:
Determining the levels of 6–TG or 6–MMP in a subject
necessarily involves a transformation. Some form of
manipulation, such as the high pressure liquid chromatography
method specified in several of the asserted dependent claims or
some other modification of the substances to be measured, is
necessary to extract the metabolites from a bodily sample and
determine their concentration. As stated by Prometheus’s
expert, “at the end of the process, the human blood sample is
no longer human blood; human tissue is no longer human
tissue.” That is clearly a transformation. 51

The Federal Circuit’s opinion did take care to repeatedly refer to the
machine-or-transformation test as a “useful clue” rather than a
46.

Id. at 1349 (emphasis added).

47.

Bilski v. Kappos, 130 S. Ct. 3218, 3227 (2010).

48.

Mayo Collaborative Servs. v. Prometheus Labs., Inc., 130 S. Ct. 3543
(2010) (mem.), vacating and remanding 581 F.3d 1336 (Fed. Cir. 2009).
Bilski was decided on June 28 and certiorari was granted and the
judgment vacated and remanded in Mayo on June 29.

49.

Andrew Pollack, Court Backs Patents for Diagnostic Tests, N.Y. Times
(Dec. 17, 2010, 5:12 PM), http://prescriptions.blogs.nytimes.com/
2010/12/17/court-backs-patents-for-diagnostic-tests.

50.

Prometheus Labs., Inc. v. Mayo Collaborative Servs., 628 F.3d 1347,
1359 (Fed. Cir. 2010).

51.

Id. at 1357 (citing Decl. of Dr. Yves Théorêt in Support of Prometheus
Labs. Inc.’s Opposition to Defendants’ Motion for Summary Judgment
of Patent Invalidity under 35 U.S.C. § 101 ¶ 6, Prometheus Labs., Inc.
v. Mayo Collaborative Servs., No. 04-CV-1200 JAH (RBB) (S.D. Cal.
Mar. 29, 2007) (No. 528-2)).
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bright-line rule; however, the court’s opinion seemed to indicate that
the Bilski holding did little to change the Federal Circuit’s prior
ruling. 52
Following this second defeat in the Federal Circuit, Mayo once
again filed a petition for certiorari, which was granted. 53 The final
hurdle in the winding procedural road to the Supreme Court came
just prior to oral arguments in December 2011, when Prometheus
revealed to the Court that Nestle had purchased the company the
prior July. 54 Though seemingly unrelated to the medical patents at
issue, it emerged that Justice Breyer’s wife owned stock in Nestle,
which would have necessitated his recusal from the proceedings. 55
However, the Nestle stock was sold on the morning of December 7,
which permitted Justice Breyer to be present that afternoon for oral
arguments and to go on to write the Court’s opinion. 56
B.

A Unanimous Decision: Analyzing Application
Rather than Transformation

Though propelled by dual Federal Circuit victories, Prometheus
was soundly defeated at the Supreme Court in a 9–0 decision on
March 20, 2012. 57 In a broad sense, the Court agreed with the original
ruling of the California District Court, holding that the Prometheus
patents simply described the relationship between thiopurine dosage
and patent side effects, which is a natural law and therefore
unpatentable subject matter under 35 U.S.C. § 101. 58
Following the examples of each of the preceding courts, the
Supreme Court relied on the following language from the ’623 patent
as the representative scope of the invention for analyzing
patentability:
A method of optimizing therapeutic efficacy for treatment of an
immune-mediated gastrointestinal disorder, comprising:

52.

See id. at 1355 (“Thus, the Court did not disavow the machine-ortransformation test. And, as applied to the present claims, the ‘useful and
important clue, an investigative tool,’ leads to a clear and compelling
conclusion . . . that the present claims pass muster under § 101.”).

53.

Mayo Collaborative Servs. v. Prometheus Labs., Inc., 131 S. Ct. 3027
(2011) (granting certiorari).

54.

Liptak, supra note 29, at B3.

55.

Id.

56.

Id.

57.

Mayo Collaborative Servs. v. Prometheus Labs., Inc., 132 S. Ct. 1289,
1292, 1305.

58.

Id. at 1305.
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(a) administering a drug providing 6-thioguanine to a subject
having said immune-mediated gastrointestinal disorder; and
(b) determining the level of 6-thioguanine in said subject having
said immune-mediated gastrointestinal disorder,
wherein the level of 6-thioguanine less than about 230 pmol per
8×108 red blood cells indicates a need to increase the amount of
said drug subsequently administered to said subject and
wherein the level of 6-thioguanine greater than about 400 pmol
per 8×108 red blood cells indicates a need to decrease the
amount of said drug subsequently administered to said subject. 59

Justice Breyer emphasized that the patents simply stated “that if
the levels of 6–TG in the blood (of a patient who has taken a dose of
a thiopurine drug) exceed about 400 pmol per 8×108 red blood cells,
then the administered dose is likely to produce toxic side effects.” 60
Thus, the patents merely contained a procedural recitation,
instructing doctors to (1) measure the current level of the relevant
metabolite through any available means, (2) use the laws of nature to
calculate the patient’s toxicity limits, and (3) reconsider the
thiopurine dosage in light of the natural law. 61 In the above three
succinct steps, Justice Breyer explained that the patents lacked the
critical element of an application of a law of nature and instead
amounted to no more than a recitation of natural laws.
The Court chided the Prometheus patents for encompassing
“nothing significantly more than an instruction to doctors to apply
the applicable laws [of nature] when treating their patients” and using
only “what is [a] well-understood, routine, conventional activity,
previously engaged in by those in the field.” 62 The Court’s opinion gave
credence to the “transformative” aspect of the machine-or-transformation
test by noting that the central issue before the Court hinged on “whether
the . . . processes have transformed . . . unpatentable natural laws into
patent-eligible applications of those laws.” 63 But the Court did not accept
the Federal Circuit’s reliance on the process steps of high-pressure liquid
59.

Id. at 1295 (citing claim 1 of Method of Treating IBD/Crohn’s Disease
& Related Conditions Wherein Drug Metabolite Levels in Host Blood
Cells Determine Subsequent Dosage, U.S. Patent No. 6,355,623 col. 20
ll. 10–20 (filed Apr. 8, 1999)). The Court clarified that “[f]or present
purposes we may assume that the other claims in the patents do not
differ significantly from claim 1.” Id.

60.

Id. at 1296–97.

61.

Id. at 1299.

62.

Id. at 1292, 1298.

63.

Id. at 1294.
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chromatography and other lab work that “transforms” the patient’s
blood sample to a different “thing” in order to extract and measure
metabolites. 64 The Court held that the actions of administering the
thiopurine drug and subsequently measuring the metabolites obviously constituted necessary interventions; however, the invention as a
whole simply encompassed a patient’s internal response to a dose of
medicine, which occurs entirely independent of outside involvement. 65

III. The Impact of Mayo on Future
Patent Examination and Litigation
The U.S. Patent and Trademark Office (USPTO) governs all
aspects of applying for, examining, and obtaining a patent. The
USPTO responded almost immediately to the Mayo holding and issued
a short brief to update patent examiners on the changes to their § 101
analysis on March 21, 2012, one day after the Court’s decision in
Mayo. 66 The USPTO then further updated the guidance measures in
July with a lengthier Guidance Memo. 67 Thus, the USPTO has clearly
taken proactive measures to ensure the widespread precedential impact
of the Mayo holding on subject matter eligibility inquiries. There is,
however, some uncertainty as to whether the Federal Circuit will be as
willing to comply.
A.

New 35 U.S.C. § 101 Patent Examination Procedures
in the Wake of the Mayo Ruling

In general, patents are either granted or denied as a result of
ongoing communications between an inventor and an examiner at the
USPTO. Patent applications are reviewed by the examiner for
compliance with the Patent Act, and the examiner is required to
interpret the application in the broadest terms that would be
reasonable to a person of ordinary skill in the art. 68 Thus, the process

64.

Prometheus Labs., Inc. v. Mayo Collaborative Servs., 628 F.3d 1347,
1355, 1357 (Fed. Cir. 2010).

65.

Mayo, 132 S. Ct. at 1297.

66.

Memorandum from Andrew H. Hirshfeld, Assoc. Comm’r for Patent
Examination Policy, on the Supreme Court Decision in Mayo
Collaborative Services v. Prometheus Laboratories, Inc. (Mar. 21, 2012),
available at http://www.uspto.gov/patents/law/exam/mayo_prelim_
guidance.pdf.

67

See infra Part III.A.

68.

See Memorandum from Andrew H. Hirshfeld, Assoc. Comm’r for Patent
Examination Policy, on the 2012 Interim Procedure for Subject Matter
Eligibility Analysis of Process Claims Involving Laws of Nature 2 (July
3, 2012), available at http://www.uspto.gov/patents/law/exam/2012
_interim_guidance.pdf [hereinafter 2012 Guidance Memo] (“Establish the
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of patenting an invention is, in essence, a back-and-forth
“conversation” between the applicant and examiner to accept, reject,
amend, and clarify the description and wording of the invention in
search of patentability. Any granted patents, including the two at
issue in Mayo, have a presumption of validity since they were
approved by a USPTO examiner. 69
On July 3, 2012, the USPTO issued a memorandum outlining the
new analytic methods patent examiners should use in evaluating
patentable subject matter in light of the Court’s holding in Mayo. 70
The new Guidance Memo sets forth revised procedures with the
specific intention that if Prometheus’s patent applications were before
an examiner today, they would not be approved as patentable subject
matter.
The new USPTO criterion sets forth a three-prong inquiry that
analyzes subject matter eligibility in a question and answer format:
(1) Is the . . . invention directed to a process, defined as an act,
or a series of acts or steps? . . .
(2) Does the [invention] focus on use
natural phenomenon, or naturally
correlation (collectively referred to
herein)? (Is the natural principle a
[invention]?) . . .

of a law of nature, a
occurring relation or
as a natural principle
limiting feature of the

(3) Does the [invention] include additional elements/steps or a
combination of elements/steps that integrate the natural
principle into the . . . invention such that the natural
principle is practically applied, and [is] sufficient to ensure
that the [invention] amounts to significantly more than the
natural principle itself? (Is it more than a law of nature
[plus] the general instruction to simply “apply it”?) 71

Inquiry 1 simply serves as a threshold question regarding whether
Mayo is applicable to the type of invention disclosed in the patent
application. Inquiry 2 then describes the category of potentially

broadest reasonable interpretation of the claims when read in light of the
specification and from the view of one of ordinary skill in the art.”).
69.

See 35 U.S.C. § 282 (2006).

70.

2012 Guidance Memo, supra note 68. The 2012 Guidance Memo
superseded the analytic methods from the previous March 21
memorandum discussed in the text accompanying note 66.

71.

2012 Guidance Memo, supra note 68, at 2. The memo indicates that the
guidance therein is interim, while the USPTO awaits issuing
comprehensive guidance after the Court’s reconsideration of the Myriad
and Ultramercial cases discussed infra Part III.B. See id. at 1.
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“dangerous” subject matter that could warrant further examination. 72
The Guidance Memo clarifies inquiry 2 by defining a natural principle
to be “the handiwork of nature [that] occurs without the hand of
man.” 73 The USPTO gives the examples of the disinfecting property
of sunlight or the correlation between blood glucose levels and
diabetes as rather simplistic versions of natural principles. 74 As
discussed previously, if the patent encompasses an abstract idea
rather than a natural principle, then Bilski governs the analysis rather
than Mayo. 75 An abstract idea under Bilksi includes, for example,
mental steps or plans for performing an action. 76
Inquiry 3 is the defining question at the heart of Mayo. If
satisfied, the invention is eligible subject matter. 77 The Guidance
Memo instructs that “[a] bare statement of a naturally occurring
correlation, albeit a newly discovered natural correlation or very
narrowly confined correlation, would fail [inquiry 3].” 78 The USPTO
directly quotes the Mayo holding throughout the memo, noting that
“[a]dding steps to a natural biological process that only recite wellunderstood, routine, conventional activity previously engaged in by
researchers in the field would not be sufficient” to satisfy the subject
matter requirements of § 101. 79
The Guidance Memo provides sample applications of the threeprong inquiry, most notably to the Prometheus patents themselves. 80
The Prometheus invention would pass inquiries 1 and 2, since as
discussed in Part II.B, the correlation of thiopurine dosage to red
blood cells comprised (1) a process and (2) the use of a law of

72.

See 2012 Guidance Memo, supra note 68 (noting that the memo is
applicable in examining all patents that include “process claims in which
a law of nature, a natural phenomenon, or [a] naturally occurring
relation or correlation . . . is a limiting element or step”).

73.

Id. at 3.

74.

Id.

75.

2012 Guidance Memo, supra note 68 (stating that “[p]rocess claims that
do not include a law of nature, a natural phenomenon, or [a] naturally
occurring relation or correlation as a claim limitation” should continue
to be examined in light of their subject matter eligibility under Bilski v.
Kappos).

76.

Id. at 3.

77.

It is crucial to note the difference between “eligible subject matter”
under § 101 and the novelty, nonobviousness, and substantive filing
requirements that govern an inventor’s ability to actually be granted a
patent. See supra text accompanying notes 7–12.

78.

2012 Guidance Memo, supra note 68, at 3.

79.

Id. at 4.

80.

Id. at 8.
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nature. 81 However, if the Prometheus patent applications were
considered by an examiner today, under the new guidance rules, the
inventor would be barred from patenting under inquiry 3. 82 This is
because, as noted by the Court, the Prometheus patents essentially
present a law of nature with the general instructions “to apply the
laws in question.” 83 Patentable subject matter requires additional
steps so that the invention amounts to substantially more than a
recitation of a natural principle. 84
B.

Will the Federal Circuit Acquiesce to the Mayo Holding?

Following the Mayo decision, the Supreme Court vacated and
remanded two cases to the Federal Circuit for reconsideration of their
subject matter patentability in light of the Court’s holding. The first
case, WildTangent, Inc. v. Ultramercial, LLC, 85 has not yet been
reheard by the Federal Circuit. The § 101 inquiry at issue in
Ultramercial is the eligibility of a patent covering a method of
distributing copyrighted material, such as songs or movies, over the
Internet in exchange for a consumer viewing an advertisement. 86 The
technology relates to the widely-debated issue of patenting software,
which at first impression seems far removed from the medical field
and the realm of natural laws. But the now-vacated Ultramercial
Federal Circuit opinion seemed to tie the principles of Bilski to those
of Mayo in noting that “[a]lthough abstract principles are not eligible
for patent protection, an application of an abstract idea may well be
deserving of patent protection.” 87 Thus, the Supreme Court’s decision
to vacate and remand Ultramercial may indicate an intention to
extend Mayo’s strict-eligibility requirements for a patent to
81.

See id. (defining the relevant analysis for patentability).

82.

See id. (rejecting the example claim “because [it] is directed to nonstatutory subject matter because it is not a patent-eligible practical
application of a law of nature”).

83.

Mayo Collaborative Servs. v. Prometheus Labs., Inc., 132 S. Ct. 1289,
1299 (2012).

84.

It is important to note that an initial rejection from an examiner does
not foreclose future patentability. Thus, the Guidance Memo notes
potential arguments an applicant may present following an initial
rejection under the Prometheus three-pronged inquiry. See 2012
Guidance Memo, supra note 68, at 9 (“It would . . . be proper for the
applicant to present persuasive arguments that the additional steps add
something significantly more to the claim than merely describing the
natural principle. A showing that the steps are not routine, well-known
or conventional could be persuasive.”).

85.

WildTangent, Inc. v. Ultramercial, LLC, 132 S. Ct. 2431 (2012) (mem.),
vacating and remanding 657 F.3d 1323 (Fed. Cir. 2011).

86.

Ultramercial, LLC v. Hulu, LLC, 657 F.3d 1323, 1324 (Fed. Cir. 2011).

87.

Id. at 1327 (emphasis added).
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incorporate an application that is significantly more than reciting a
law of nature, or, in this case, an abstract idea.
The second case remanded, Association for Molecular Pathology
v. Myriad Genetics, Inc., was reheard by the Federal Circuit on
August 16, 2012, and has far more obvious ties to the Mayo
decision. 88 In essence, the dispute questions three aspects surrounding
Myriad’s patents over the human genes associated with a person’s
predisposition to suffer ovarian or breast cancers: Can Myriad patent
(1) the isolation of the genes, (2) the methods “for comparing DNA
sequences,” or (3) the process of screening the genes to evaluate
cancer risk? 89 The Myriad case has been closely followed not
necessarily for the intricacies of its § 101 arguments, but
predominantly because of the moral and political debates surrounding
the concept of patenting human genes. 90
The New York Times noted that Myriad’s stock dropped
immediately following the Mayo decision, based on investors’ fears
that the company’s gene patents would be reconsidered as laws of
nature and thus invalid. 91 But in spite of the Supreme Court’s holding
in Mayo, the Federal Circuit in Myriad held that “Mayo does not
control the question of patent-eligibility” of the Myriad patents,
because the “isolated DNA molecules before us are not found in
nature . . . [t]hey are obtained in the laboratory and are man-made,
the product of human ingenuity.” 92 The court held that the patents
consisted of compositions of matter, which in general are a “thing”
rather than a Mayo-type law of nature or a Bilski-type abstract idea.
Therefore, the Federal Circuit upheld the validity of Myriad’s gene
88.

Ass’n for Molecular Pathology v. Myriad Genetics, Inc., 132 S. Ct. 1794
(2012) (mem.), vacating and remanding 653 F.3d 1329 (Fed. Cir. 2011).

89.

Ass’n for Molecular Pathology v. U.S. Patent and Trademark Office
(Myriad), 689 F.3d 1303, 1324 (Fed. Cir. 2012).

90.

See, e.g., Brief of Amici Curiae Rosetta Genomics, Ltd. et al. in
Support of Defendants-Appellants, Supporting Reversal at 2, Myriad,
689 F.3d 1303, 1324 (Fed. Cir. 2012) (No. 2010-1406), 2010 WL 4853324
at *2 (“This case has generated significant public comment regarding so
called ‘gene patents.’ The ACLU and Plaintiffs-Appellees have
welcomed, and in fact encouraged, the public attention and resulting
controversy.”); Daniel Fisher, D.C. Court Upholds Myriad BreastCancer Patents, Snubbing Supreme Court, Forbes (Aug. 16, 2012, 2:23
PM), http://www.forbes.com/sites/danielfisher/2012/08/16/d-c-courtupholds-myriad-breast-cancer-patents-snubbing-supreme-court (“Human
DNA is a natural entity . . . [i]t does not belong to any one company.”
(quoting American Civil Liberties Union staff attorney Chris Hansen)).

91.

Liptak, supra note 29, at B3. The Federal Circuit had earlier upheld
two patents held by Myriad Genetics claiming the process of analyzing
extracted DNA for the genes BRCA1 and BRCA2, in which mutations
indicate a risk of developing breast or ovarian cancers. Id.

92.

Myriad, 689 F.3d at 1325.
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patents without a truly comprehensive consideration of Mayo’s
precedent. 93
Thus, the Federal Circuit in essence has defined human DNA to
be outside the realm of natural laws. 94 But Judge Moore’s concurring
opinion raised a question: “Does the isolation process change the DNA
from an unpatentable manifestation of nature into a patentable
composition of matter?” Judge Moore went on to suggest that the
task of addressing such complicated scientific principles is better left
to Congress than the Court. 95 The Federal Circuit judges did not
reach a collective opinion in Myriad, and the holding has been noted
as a veritable “snub” to the Supreme Court’s Mayo decision. 96 But
just as the Prometheus patents were twice upheld by the Federal
Circuit before being defeated in the Supreme Court, commentators
predict that the Myriad case may reach the Court in an upcoming
term, perhaps with a very different outcome. 97

Conclusion
The Mayo dispute was unquestionably controversial and garnered
several amici curiae briefs on each side. 98 The Court noted that medical
experts strongly opposed patentability because of the ever-present
concern of undue monopolization and the risk of “disproportionately
tying up the use of . . . underlying natural laws,” which would inhibit
medical researchers from making further discoveries. 99
93.

Id.

94.

See id. at 1331 (“The remand of this case for reconsideration in light of
Mayo might suggest . . . that the composition claims are mere reflections
of a law of nature. Respectfully, they are not . . . [t]hey are the products
of man, albeit following, as all materials do, laws of nature.”).

95.

Id. at 1340, 1345 (Moore, J., concurring).

96.

Fisher, supra note 90.

97.

See id. (“There’s still a great deal of uncertainty because the Supreme
Court has not had the final word on this issue.” (quoting Antoinette
Konski, an intellectual property attorney at Foley and Lardner in Palo
Alto, California)); Jonathan Stempel, Myriad Wins Gene Patent Ruling
from US Appeals Court, Reuters (Aug. 16, 2012), http://www.
reuters.com/article/2012/08/16/us-myriad-patent-idUSBRE87F12K2012
0816 (“Although the decision will probably be appealed to the U.S.
Supreme Court . . . today . . . the decision is ‘a win.’” (quoting biotech
patent attorney Tim Worral of Dorsey and Whitney)).

98.

The Court cited the following organizations by name: the American
Medical Association, the American College of Medical Genetics, the
American Hospital Association, the American Society of Human
Genetics, the Association of American Medical Colleges, and the
Association for Molecular Pathology. Mayo Collaborative Servs. v.
Prometheus Labs., Inc., 132 S. Ct. 1289, 1304–05 (2012).

99.

Id. at 1294.
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While most patent applications present a tangible invention or
“thing” and easily traverse the § 101 threshold, recent advancements
in the biological and computer sciences have necessitated a thorough
reexamination of our ability to patent “anything under the sun that is
made by man.” 100 The Supreme Court’s years of silence on subject
matter eligibility prior to Bilski and Mayo resulted in glaring
inconsistencies among patent examiners, district courts, and the
Federal Circuit, which have weakened the integrity of the statutory
language. But now the Supreme Court and the USPTO have begun to
take proactive measures to redefine the outer boundaries of patenteligible subject matter. Perhaps Ultramercial, along with a potential
future appeal in Myriad, will resolve the remaining inconsistent
approaches to applying § 101 doctrine.
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100. See supra text accompanying note 19.
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